■ 英語タイトル：Central Nervous System (CNS) Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
	■ 発行会社/調査会社：IMARC ■ 商品コード：IMARC23AP141 ■ 発行日：2023年3月2日    最新版(2025年又は2026年)版があります。お問い合わせください。 ■ 調査対象地域：グローバル ■ 産業分野：医療 ■ ページ数：142 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール

The global central nervous system (CNS) therapeutics market size reached US$ 131.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 214.6 Billion by 2028, exhibiting a growth rate (CAGR) of 6.8% during 2023-2028.

The central nervous system (CNS) represents a vital part of the nervous system that comprises of the brain and the spinal cord. It integrates the received information, thereafter coordinating and controlling the activities of all parts of the body. CNS therapeutics primarily include anesthetics, anticonvulsants, CNS stimulants, muscle relaxants, narcotic analgesics, sedatives, etc. They are widely adopted in the treatment procedures of Parkinson’s disease, depression, Alzheimer’s disease, epilepsy, traumatic brain, spinal cord injury, CNS cancer, etc.

Central Nervous System (CNS) Therapeutics Market Trends:
The elevating prevalence of mental illness and lifestyle-associated CNS disorders, including anxiety, depression, hypertension, etc., is primarily driving the global CNS therapeutics market. In line with this, the growing geriatric population, who are more prone to chronic neurological ailments such as Alzheimer’s disease and Parkinson’s disease, is also propelling the global market. Additionally, the emerging popularity of generic neurologic drugs across developing countries on account of their affordability is further augmenting the market for CNS therapeutics. Apart from this, continuous innovations in CNS treatment procedures, such as the development of gene therapy, neurostimulation tools, and neural transplantation techniques, are also stimulating the market growth. These approaches prolong the action of unremitting dopaminergic stimulation medicines and control disease progression. Moreover, the introduction of novel drug-delivery systems that provide ease of administration and availability of different dosage forms is further creating a positive outlook for the global CNS market. For instance, transdermal patches are gaining traction in the field of neurology to treat CNS disorders as they offer a precise amount of medicine and relief for around 24 hours. Besides this, the increasing focus of the government and non-government organizations on creating awareness regarding numerous CNS disorders and the accessibility to multiple treatment options is also catalyzing the market growth. Moreover, the launch of favorable guidelines to support faster approvals of pipeline drugs for neurodegenerative diseases and clinical trials that encourage the entry of new products is expected to drive the global central nervous system therapeutics market in the coming years.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global central nervous system (CNS) therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on disease and application.

Breakup by Disease:
Neurodegenerative Diseases
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Huntington’s Disease
Amyotrophic Lateral Sclerosis
Others
Neurovascular Diseases
CNS Trauma
Mental Health
Anxiety Disorders
Epilepsy
Mood Disorders
Psychotic Disorders
Others
Infectious Diseases
CNS Cancer
Others

Breakup by Application:
Hospital
Clinic
Homecare
Others

Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AstraZeneca plc, Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG (Roche Holding), H. Lundbeck A/S, Merck & Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report
1. What was the size of the global Central Nervous System (CNS) therapeutics market in 2022?
2. What is the expected growth rate of the global Central Nervous System (CNS) therapeutics market during 2023-2028
3. What are the key factors driving the global Central Nervous System (CNS) therapeutics market?
4. What has been the impact of COVID-19 on the global Central Nervous System (CNS) therapeutics market?
5. What is the breakup of the global Central Nervous System (CNS) therapeutics market based on the disease?
6. What are the key regions in the global Central Nervous System (CNS) therapeutics market?
7. Who are the key players/companies in the global Central Nervous System (CNS) therapeutics market?